PCRX Valuation

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

PCRX Relative Valuation

PCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PCRX is overvalued; if below, it's undervalued.

Historical Valuation

Pacira Biosciences Inc (PCRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 8.60 is considered Undervalued compared with the five-year average of 14.65. The fair price of Pacira Biosciences Inc (PCRX) is between 25.62 to 52.11 according to relative valuation methord. Compared to the current price of 24.35 USD , Pacira Biosciences Inc is Undervalued By 4.96%.

Relative Value

Fair Zone

25.62-52.11

Current Price：24.35

4.96%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.48

P/B

Median3y

2.07

Median5y

3.05

15.73

FCF Yield

Median3y

10.95

Median5y

7.43

Competitors Valuation Multiple

The average P/S ratio for PCRX's competitors is 8.57, providing a benchmark for relative valuation. Pacira Biosciences Inc Corp (PCRX) exhibits a P/S ratio of 1.51, which is -82.39% above the industry average. Given its robust revenue growth of 3.32%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

PCRX.O

Pacira Biosciences Inc